"HLA-DR1 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An HLA-DR antigen associated with HLA-DRB1 CHAINS that are encoded by DRB1*01 alleles.
| Descriptor ID |
D015798
|
| MeSH Number(s) |
D12.776.395.550.509.400.440.400.010 D12.776.543.550.440.400.440.400.010 D23.050.301.500.400.400.440.400.010 D23.050.301.500.450.400.440.389.500 D23.050.705.552.410.400.440.389.010 D23.050.705.552.450.400.440.389.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "HLA-DR1 Antigen".
Below are MeSH descriptors whose meaning is more specific than "HLA-DR1 Antigen".
This graph shows the total number of publications written about "HLA-DR1 Antigen" by people in this website by year, and whether "HLA-DR1 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 2 | 2 | 4 |
| 2005 | 1 | 1 | 2 |
| 2007 | 0 | 3 | 3 |
| 2008 | 2 | 0 | 2 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 2 | 3 |
| 2015 | 2 | 0 | 2 |
| 2016 | 2 | 0 | 2 |
| 2018 | 1 | 0 | 1 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "HLA-DR1 Antigen" by people in Profiles.
-
Ramesh KM, Lu L, Stern LJ. T Cell Assay to Track Presentation of an Influenza Hemagglutinin Epitope Presented by the MHC-II Protein HLA-DR1. Methods Mol Biol. 2026; 3007:255-273.
-
Negroni MP, Stern LJ. The N-terminal region of photocleavable peptides that bind HLA-DR1 determines the kinetics of fragment release. PLoS One. 2018; 13(7):e0199704.
-
Hellman LM, Yin L, Wang Y, Blevins SJ, Riley TP, Belden OS, Spear TT, Nishimura MI, Stern LJ, Baker BM. Differential scanning fluorimetry based assessments of the thermal and kinetic stability of peptide-MHC complexes. J Immunol Methods. 2016 May; 432:95-101.
-
Clement CC, Becerra A, Yin L, Zolla V, Huang L, Merlin S, Follenzi A, Shaffer SA, Stern LJ, Santambrogio L. The Dendritic Cell Major Histocompatibility Complex II (MHC II) Peptidome Derives from a Variety of Processing Pathways and Includes Peptides with a Broad Spectrum of HLA-DM Sensitivity. J Biol Chem. 2016 Mar 11; 291(11):5576-5595.
-
Yin L, Maben ZJ, Becerra A, Stern LJ. Evaluating the Role of HLA-DM in MHC Class II-Peptide Association Reactions. J Immunol. 2015 Jul 15; 195(2):706-16.
-
Brown JH, Jardetzky TS, Gorga JC, Stern LJ, Urban RG, Strominger JL, Wiley DC. Pillars article: three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature. 1993. 364: 33-39. J Immunol. 2015 Jan 01; 194(1):5-11.
-
Holland CJ, Rizkallah PJ, Vollers S, Calvo-Calle JM, Madura F, Fuller A, Sewell AK, Stern LJ, Godkin A, Cole DK. Minimal conformational plasticity enables TCR cross-reactivity to different MHC class II heterodimers. Sci Rep. 2012; 2:629.
-
Huang JF, Yafawi R, Zhang M, McDowell M, Rittenhouse KD, Sace F, Liew SH, Cooper SR, Pickering EH. Immunomodulatory effect of the topical ophthalmic Janus kinase inhibitor tofacitinib (CP-690,550) in patients with dry eye disease. Ophthalmology. 2012 Jul; 119(7):e43-50.
-
Nastke MD, Becerra A, Yin L, Dominguez-Amorocho O, Gibson L, Stern LJ, Calvo-Calle JM. Human CD4+ T cell response to human herpesvirus 6. J Virol. 2012 May; 86(9):4776-92.
-
Painter CA, Negroni MP, Kellersberger KA, Zavala-Ruiz Z, Evans JE, Stern LJ. Conformational lability in the class II MHC 310 helix and adjacent extended strand dictate HLA-DM susceptibility and peptide exchange. Proc Natl Acad Sci U S A. 2011 Nov 29; 108(48):19329-34.